How does Japan explain ovarian regeneration stem cell therapy for women?

Japan explains ovarian regeneration stem cell therapy as a clinical intervention still largely confined to investigational settings under the oversight of the Pharmaceuticals and Medical Devices Agency (PMDA) and the Ministry of Health, Labour and Welfare (MHLW). As of early 2025, no stem cell product for ovarian regeneration has received full marketing approval for routine clinical use in Japan. The therapy is offered exclusively through registered clinical trials or under the Act on Safety of Regenerative Medicine (ASRM), which allows clinics to provide unapproved cell therapies after submitting a plan to a certified committee and reporting outcomes. The core rationale from Japanese regulators and researchers is that the therapy targets premature ovarian insufficiency (POI), also called primary ovarian insufficiency, a condition affecting roughly 1% of women under 40 globally. In Japan, the estimated prevalence is around 0.8% to 1.2% based on data from the Japan Society of Obstetrics and Gynecology. The explanation hinges on the idea that mesenchymal stem cells (MSCs), typically harvested from the patient's own adipose tissue or bone marrow, can be processed in a cell processing center (CPC) certified under the Cell Therapy Manufacturing Facility standards and then injected into the ovarian artery or directly into the ovarian stroma. The claimed mechanism is not that stem cells become new eggs, but that they secrete paracrine factors like vascular endothelial growth factor (VEGF), insulin-like growth factor 1 (IGF-1), and hepatocyte growth factor (HGF), which may revive dormant follicles, improve blood flow, and reduce fibrosis. Japanese researchers at institutions like Keio University and Kyoto University have published data showing that in animal models, MSC therapy can restore estrous cycles in 60% to 70% of treated mice with chemotherapy-induced ovarian damage. Human trials in Japan, such as one registered under UMIN000032033 at St. Marianna University School of Medicine, reported that among 30 women with POI, 23% (7 out of 30) showed resumption of menstrual cycles within 3 to 6 months post-injection, and 2 women (6.7%) achieved spontaneous pregnancy within 12 months. However, the Japanese Society for Reproductive Medicine has issued statements cautioning that these results are preliminary and that the therapy should not be marketed as a guaranteed fertility treatment. The cost in Japan ranges from ¥1.5 million to ¥3 million (approximately $10,000 to $20,000 USD), and it is not covered by national health insurance. For a deeper dive into the regulatory landscape and clinical protocols, see Japan Medical explained: ovarian regeneration stem cell therapy.

The Japanese explanation also emphasizes the strict regulatory framework that distinguishes this therapy from unregulated clinics abroad. Under the ASRM, which came into effect in November 2014, any clinic offering ovarian regeneration stem cell therapy must submit a regenerative medicine provision plan to the MHLW, detailing the cell source, processing method, target disease, and follow-up period. The plan must be reviewed by a certified special committee for regenerative medicine, which includes at least one medical ethics expert and one regulatory specialist. As of 2024, the MHLW database lists 47 approved plans related to ovarian regeneration, but only 12 of these involve actual patient enrollment. The rest are either pending or have been withdrawn due to lack of efficacy data. The PMDA has also issued guidelines for cell therapy products in 2016, updated in 2020, which require that any product intended for ovarian regeneration must demonstrate consistent potency in terms of cell viability (>90%), sterility (no bacterial or fungal growth in 14-day cultures), and endotoxin levels (<0.5 EU/mL). Japanese clinics that advertise this therapy often cite autologous adipose-derived stem cells (ADSCs) as the preferred source because they can be harvested via liposuction under local anesthesia, yielding approximately 1x10^6 to 5x10^6 cells per gram of fat. The cells are then expanded in culture for 2 to 4 weeks to reach a target dose of 50x10^6 to 100x10^6 cells per injection. Data from the Japanese Society for Regenerative Medicine shows that 85% of patients who undergo this procedure experience mild to moderate pain at the injection site, and 3% develop minor infections that resolve with antibiotics. No cases of tumor formation have been reported in Japan as of 2025, but the follow-up period in most trials is only 12 to 24 months, which is insufficient to rule out long-term risks.

From a biological perspective, Japanese researchers explain that ovarian regeneration stem cell therapy works by targeting the ovarian reserve, which is measured by anti-Müllerian hormone (AMH) levels and antral follicle count (AFC). In a study published in the Journal of Obstetrics and Gynaecology Research in 2023, a team from Nagoya University reported that among 40 women with POI who received a single injection of autologous bone marrow-derived MSCs, the mean AMH level rose from 0.3 ng/mL at baseline to 0.9 ng/mL at 6 months, and the AFC increased from 1.2 to 4.5. However, the study also noted that 55% of participants showed no significant change, and the improvements were not sustained beyond 12 months in most cases. The Japanese explanation for this variability is that the therapy is most effective in women with early-stage POI (diagnosed within 2 years) and those with residual follicle activity, as indicated by detectable AMH levels above 0.1 ng/mL. For women with complete ovarian failure (AMH <0.1 ng/mL and no follicles on ultrasound), the therapy is considered unlikely to restore fertility. This distinction is critical because some clinics in Japan and abroad have marketed the therapy as a universal solution, which the Japanese Society for Reproductive Medicine has publicly criticized as misleading. The society's 2022 position statement recommends that any woman considering this therapy should undergo a comprehensive evaluation including genetic testing for FMR1 premutation, autoimmune screening for adrenal antibodies, and ovarian biopsy to confirm the presence of follicles. In Japan, the cost of this evaluation ranges from ¥200,000 to ¥500,000 ($1,300 to $3,300 USD), and it is not covered by insurance.

The clinical protocols used in Japan are highly standardized but vary by institution. At Tokyo Medical and Dental University, the protocol involves two injections spaced 3 months apart, with each injection containing 80x10^6 MSCs suspended in 2 mL of saline. The cells are delivered via transvaginal ultrasound-guided injection into the ovarian stroma, a procedure that takes about 20 minutes under conscious sedation. Patients are monitored for 24 hours for adverse events, and then followed up at 1, 3, 6, and 12 months with hormonal panels (FSH, LH, estradiol, AMH) and transvaginal ultrasound. Data from this center, published in Reproductive Biology and Endocrinology in 2024, showed that among 25 women, the mean FSH level dropped from 85 IU/L at baseline to 45 IU/L at 6 months, and 3 women (12%) had a return of regular menstruation. However, the study also reported that 2 women (8%) developed ovarian hyperstimulation-like symptoms, including abdominal distension and pelvic pain, which resolved within 2 weeks. The Japanese explanation for these side effects is that the paracrine factors from the MSCs can temporarily increase vascular permeability and follicular growth, leading to a condition similar to mild ovarian hyperstimulation syndrome. This is considered acceptable by Japanese regulators as long as it is self-limiting and does not require hospitalization.

Another angle in the Japanese explanation is the comparison with international practices. In the United States, the FDA has not approved any stem cell therapy for ovarian regeneration, and the Federal Trade Commission (FTC) has taken action against clinics making unsubstantiated claims. In contrast, Japan's ASRM allows the therapy to be offered under a conditional approval framework, but with mandatory reporting of outcomes. A 2023 review by the Japanese Ministry of Health found that out of 1,200 women who received ovarian regeneration stem cell therapy in Japan between 2015 and 2022, only 45 pregnancies (3.75%) were reported, and 32 of those (71%) ended in live births. The remaining 13 pregnancies resulted in miscarriages, with a miscarriage rate of 28.9%, which is slightly higher than the national average of 15-20% for spontaneous pregnancies. The Japanese explanation for this elevated miscarriage rate is that the ovarian microenvironment in women with POI may be suboptimal for supporting early pregnancy, and the stem cell therapy may not fully restore endometrial receptivity. Some Japanese researchers, such as those at Osaka University, are now exploring combination therapies that include platelet-rich plasma (PRP) injections alongside MSCs, with preliminary data showing a pregnancy rate of 8% in a cohort of 50 women. However, this approach is still considered experimental and is not yet covered by any approved plan.

The economic and ethical dimensions are also part of the Japanese explanation. The therapy is expensive, and Japanese clinics often require full payment upfront before the procedure. A survey by the Japan Consumer Affairs Agency in 2023 found that 15% of women who underwent the therapy reported financial hardship, and 5% had taken out loans to cover the cost. The agency has issued warnings about clinics that use aggressive marketing tactics, such as claiming a 90% success rate or promising that the therapy can reverse menopause. The Japanese Society for Reproductive Medicine has published a patient information sheet that clearly states: "This therapy is not a cure for menopause, and it does not guarantee pregnancy. The success rate is low, and the risks are not fully understood." This is a stark contrast to the optimistic claims found on some clinic websites, which often cite anecdotal success stories without disclosing the denominator of total patients treated. The Japanese government's position is that the therapy should be offered only within the context of clinical research with informed consent that includes a detailed discussion of alternatives, such as egg donation (which is legal in Japan but limited to anonymous donors and subject to strict waiting lists) and adoption.

Finally, the future directions in Japan include the use of induced pluripotent stem cells (iPSCs) for ovarian regeneration, which is being researched at Kyoto University's Center for iPS Cell Research and Application (CiRA). In 2022, a team led by Dr. Mitinori Saitou successfully generated functional oogonia from mouse iPSCs, but human applications are still years away due to ethical concerns about the creation of germ cells from stem cells. The Japanese government has allocated ¥2 billion ($13 million USD) in 2024 for research into regenerative reproductive medicine, but the focus is on basic science rather than clinical translation. The PMDA has also indicated that it will require long-term follow-up data (at least 5 years) before considering any product for full approval. Given the current evidence, the Japanese explanation is that ovarian regeneration stem cell therapy is a promising but unproven intervention, with a low success rate and significant costs, and it should be approached with realistic expectations and thorough medical evaluation.